Publication: Journal of Surgical Research
Abstract
Tranexamic acid (TXA) reduces mortality in traumatic brain injury when given early, but intravenous access can be difficult to obtain in prehospital settings, making intraosseous administration an attractive alternative that has not previously been studied in humans. This retrospective analysis of a prehospital TXA trial compared total drug exposure (AUC, calculated using Phoenix WinNonlin) between intraosseous and intravenous TXA administration in patients with moderate or severe traumatic brain injury, stratified by renal function. No significant differences in mean AUC were observed between intraosseous and intravenous routes for either the 2-g bolus or 1-g bolus/1-g infusion dosing regimens. These preliminary findings suggest intraosseous and intravenous TXA administration may result in similar total drug exposure, though larger studies with clinical outcomes are needed to confirm this.
Author(s): Newman ZC, Ogbeifun VO, Barbosa CE, McKinley WI, Benjamin AJ, Munar MY, Pramuka PE, McGovern KD, Nordgren RK, Schreiber MA, Rowell SE
Published: September 2, 2024
Phoenix WinNonlin: Intraosseous vs. Intravenous PK
Phoenix WinNonlin calculated total drug exposure behind this intraosseous-versus-intravenous TXA comparison, supporting an alternative route for trauma care in the field. As part of a Phoenix platform relied on by 17 global regulatory agencies, Phoenix WinNonlin’s results can flow directly into PK Submit for CDISC-compliant submission packages.
